This Phase I clinical trial, sponsored by the Chinese PLA General Hospital, investigates the safety and feasibility of CRISPR-Cas9 mediated PD-1 gene knockout in CAR-T cells targeting mesothelin-positive solid tumors, particularly pancreatic cancer, cholangiocarcinoma, and ovarian cancer. The market for CAR-T therapies is rapidly expanding, particularly in oncology, with increasing interest in personalized and genetically modified cell therapies. The trial's focus on mesothelin, a promising target in solid tumors, positions it competitively within the CAR-T landscape. However, the trial's current status is 'recruiting,' and further data on safety and efficacy will be critical for attracting potential partnerships or investments. The success of this trial could lead to significant advancements in treatment options for patients with limited responses to existing therapies, thereby enhancing the commercial viability of the asset.